Research programme: orphan disease therapeutics - GlaxoSmithKline

Drug Profile

Research programme: orphan disease therapeutics - GlaxoSmithKline

Alternative Names: Rare disease therapeutics - GSK

Latest Information Update: 24 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Unspecified

Most Recent Events

  • 24 Jun 2016 Phase-I/II clinical trials in Undefined indication in United Kingdom (unspecified route) (Oxford Biomedica pipeline, June 2016)
  • 28 Oct 2015 GlaxoSmithKline in-licenses LentiVector® platform technology from Oxford BioMedica
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top